Ro (company)

Roman Health Ventures Inc., doing business as Ro, is an American telehealth company that diagnoses patients, and subsequently prescribes and delivers treatments and ongoing care.

Uses your system voice; voice and rate in settings.

Snapshot

≈ 2 min read

Names in other languages

No names in other languages are held for this entry yet.

Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.

Roman Health Ventures Inc., doing business as Ro, is an American telehealth company that diagnoses patients, and subsequently prescribes and delivers treatments and ongoing care. The company is headquartered in New York City. Ro has nationwide telehealth, labs, and pharmacy services across the continental United States. Ro has been used by at least one patient in every county in the United States and has been utilized in 98% of primary care deserts.

Obesity treatment

Ro began treating obesity through supplying Gelesis100. In January 2023, Ro expanded obesity treatment through GLP-1 receptor agonists through its Body Program. An ad campaign for Ro’s Body Program on the New York City Subway was criticized for being too "evocative".

After the medication gained FDA approval in 2023, Ro began prescribing Zepbound to medically-eligible patients through its Body Program. In May 2024, in response to continual GLP-1 supply shortages, Ro launched a GLP-1 Supply Tracker to help people crowdsource information about medication supply and availability, receiving tens of thousands of reports from across the country.

Later that year, the company also launched a free tool for anyone to learn more about their insurance coverage of GLP-1 receptor agonists. In December of 2024, Ro announced that they were working with pharmaceutical company Eli Lilly to offer Zepbound vials via the platform through an integration with LillyDirect.

Ro later announced an integration with Novo Nordisk to offer Wegovy at a reduced price. In January 2026, Novo Nordisk partnered with Ro, among other telehealth providers to offer the Wegovy pill, the first FDA-approved GLP-1 medication in pill form. In 2025, Ro announced partnerships with Charles Barkley and Serena Williams for their GLP-1 treatment program.

During the announcement, Williams told reporters that she partnered with Ro to destigmatize GLP-1s as a treatment for weight management.

Text derived from https://en.wikipedia.org/w/index.php?oldid=1360978661 under CC BY-SA 4.0; modifications have been made.

Sources cited in this revision

38 named source(s) extracted from the cited revision. A source with no author is shown by its publication; nothing is invented.